Follow-On Offering

Healthcare
Follow-On Offering

Summary

Baird served as a co-manager on this offering

About

TESARO, Inc. (“TESARO” or the “Company”) (NASDAQ: TSRO) recently completed a follow-on offering of 3,200,000 shares of common stock at a price of $31.50 per share, generating gross proceeds of approximately $100.8 million. The Company intends to use the net proceeds from the offering to fund its development programs, including clinical trials for its product candidates, rolapitant, niraparib and TSR-011; and for working capital and general corporate purposes.

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. TESARO has in-licensed and is currently developing three product candidates, rolapitant (Phase 3), niraparib (Phase 3) and TSR-011 (Phase 1/2a). TESARO is headquartered in Waltham, Massachusetts.

For additional information about this transaction, please contact:

David Schechner 617-426-5424
Lance Lange (414) 765-7079
Ryan Mausehund 650-858-3817
Satoshi Matsumoto 312-609-5446
Manish Gupta 414-765-3802
Healthcare
Follow-On Offering
Date
January 2014
Company
TESARO, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share